Articles tagged "Efficacy"

2022 American Transplant Congress
Complement 5 Regulation Ameliorates Antibody-Mediated Rejection After Liver Transplantation in Rats
T. Tajima¹, K. Hata¹, J. Kusakabe¹, H. Miyauchi¹, X. Zhao¹, S. Kageyama¹, T. Okamoto¹, Y. Wang², E. Hatano¹
¹Dept. of HBP Surgery & Transplantation, Kyoto University, Kyoto, Japan, ²Alexion Pharmaceuticals Inc., New Haven, CT
*Purpose: Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody (DSA)-positive or blood-type incompatible organ transplantation. Since AMR significantly deteriorates transplant outcomes, there is…
2022 American Transplant Congress
Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on Covid-19 Infection in Kidney Transplant Recipients
N. Sutharattanapong, S. Thotsiri, S. Kantachuvesiri, P. Wiwattanathum
Excellent Center of Organ Transplantation, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
*Purpose: Most developing countries do not have access to high-efficiency mRNA vaccine. In Thailand, the first and most available vaccines were inactivated, and later on,…
2022 American Transplant Congress
External Validation of the Abbreviated Ibox Scoring System at One-Year Post Kidney Transplant as a Surrogate Endpoint for Death-Censored Graft Survival
A. Klein¹, L. Kosinski², R. Muse², A. Loupy³, O. Aubert³, G. Divard³, M. Stegall⁴, I. Helanterä⁵, W. E. Fitzsimmons¹, I. O'Doherty¹
¹Transplant Therapeutics Consortium, Critical Path Institute, Tucson, AZ, ²Critical Path Institute, Tucson, AZ, ³Paris Transplant Group, Paris, France, ⁴Mayo Clinic, Rochester, MN, ⁵Helsinki University Hospital, Helsinki, Finland
*Purpose: The Transplant Therapeutics Consortium seeks to translate the iBox from Loupy et al., 2019 into a surrogate endpoint for five-year death-censored graft survival after…
2022 American Transplant Congress
Safety and Efficacy at 4 Years in Post-Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide (TAF) for HBV Prophylaxis
E. Gane¹, B. George¹, D. Ray-Chaudhuri¹, T. Mules¹, C. D. Holt², H. Wang², V. Suri², A. Gaggar², A. Osinusi², J. Flaherty²
¹Auckland City Hospital and University of Auckland, Auckland, New Zealand, ²Gilead Sciences, Inc., Foster City, CA
*Purpose: Recommended antiviral prophylaxis to prevent recurrent HBV infection after liver transplantation includes tenofovir disoproxil fumarate (TDF). However, given risks of bone/renal toxicity associated with…
2022 American Transplant Congress
Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Solid Organ Transplant Recipients
L. Selznick, J. Contreras, K. Klein, C. Long, R. Hall, S. Bhayana, H. Sweiss
University Health, San Antonio, TX
*Purpose: To determine the safety and efficacy of sodium glucose cotransporter-2 inhibitors (SGLT2i) in solid organ transplant.*Methods: This is a retrospective review of adult kidney,…
2022 American Transplant Congress
Mhealth Coaching Improves Patient Activation and Nutritional Behaviors in Diverse Renal Transplant Recipients
M. Pollack¹, N. Stauffer², H. Lee², I. Satoru², M. Ellis³, C. Diamantidis³, S. Docherty⁴, E. T. Chambers⁵
¹Psychiatry, Duke University, Durham, NC, ²Biostatistics, Duke University, Durham, NC, ³Internal Medicine, Duke University, Durham, NC, ⁴School of Nursing, Duke University, Durham, NC, ⁵Pediatrics, Duke University, Durham, NC
*Purpose: Kidney transplant recipients who are not actively engaged in their care and lack self-management skills have poor transplant outcomes. These suboptimal outcomes are disproportionately…
2022 American Transplant Congress
Outcomes of Very Small Pediatric Donor Kidneys Utilizing Belatacept-Based Immunosuppression in Adult Recipients
K. Heinen¹, A. Carlson², A. Chan¹, M. M. Eiting¹, T. Larson¹, B. Sirandas¹, C. Truax¹, L. Smith¹
¹University of Utah Health, Salt Lake City, UT, ²Medical University of South Carolina, Johnston, SC
*Purpose: Due to the lack of data utilizing belatacept as primary immunosuppression for adult recipients of very small pediatric donor kidneys, this study seeks to…
2022 American Transplant Congress
Long-Term Effects of Conversion from Calcineurin Inhibitors to Sirolimus for the Recipients with Low Immunological Risk in Renal Allograft
Q. Wu, J. Chen, D. Cheng, X. Ni, X. Li, K. Xie, W. Jiqiu
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University Jinling School of Medicine, Nanjing, China
*Purpose: To observe the long-term effects and prognosis of conversion from calcineurin inhibitors (CNIs) to sirolimus in biopsy-proven low immunological risk renal transplant recipients (RTRs).*Methods:…
2022 American Transplant Congress
Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients
D. Rodríguez-Espinosa, E. Montagud-Marrahi, J. Cacho, C. Arana, N. Taurizano, E. Hermida, J. Del Risco, J. Casals, A. Rosario, E. Cuadrado, N. Rodríguez, I. Revuelta, B. Bayès, P. Ventura-Aguiar, F. Cofan, E. Poch, F. Oppenheimer, M. Vera, L. Rodas, F. Maduell, F. Diekmann, A. Cases, J. Broseta, D. Cucchiari
Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain
*Purpose: The increased COVID-19 severity observed in kidney transplant recipients (KTR) has been widely reported. In addition, several studies have shown a reduced humoral and…
2022 American Transplant Congress
Efficacy and Safety of Denosumab on Osteoporosis in Kidney Transplant Recipients
W. Park, J. Kwon, J. Lim, Y. Kim, J. Paek, K. Jin, S. Han
Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
*Purpose: The use of immunosuppressive agents, especially glucocorticoids, are associated with increased risks of bone loss in kidney transplant recipients (KTRs). Denosumab, a potent antiresorptive…

1
2
3
…
14
Next Page »